Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;37(2):200-202.
doi: 10.1038/s41433-022-02246-5. Epub 2022 Sep 16.

Approved biosimilar ranibizumab-a global update

Ashish Sharma  1 , Mineo Kondo  2 , Chiharu Iwahashi  3 , Nikulaa Parachuri  4 , Nilesh Kumar  5 , Francesco Bandello  6 , Anat Loewenstein  7 , Baruch D Kuppermann  8
Affiliations

Approved biosimilar ranibizumab-a global update

Ashish Sharma et al. Eye (Lond). 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AS: Consultant: for Novartis, Allergan, Bayer and Intas. MK: Clinical Research: Alcon, Bayer, Hoya, Kowa, Novartis, Otsuka, Santen, Senju; Consultant: Chugai, Daicel, Novartis, Ono, Sanofi, Asahi-Kasei, Senju. CI: none. FB: Consultant: Allergan, Bayer, Boehringer Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. BDK: Clinical Research: Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, IvericBio, jCyte, Novartis, Regeneron; Consultant: Alimera, Allegro, Allergan, Eyebio, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics/Ripple Therapeutics, IvericBio, jCyte, Novartis, Regeneron, Revana, Theravance Biopharma. NK: none. NP: none.

References

    1. FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna). 2022. https://investors.biogen.com/news-releases/news-release-details/fda-appr....
    1. Ranibizumab Biosimilar (Byooviz) Gains EU Marketing Authorization. 2022. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-....
    1. Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139:68–76. doi: 10.1001/jamaophthalmol.2020.5053. - DOI - PMC - PubMed
    1. Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021:bjophthalmol-2021-319637. - PMC - PubMed
    1. European Commission approves FYB201/Ranivisio®1 (Ranivisio—Ranibizumab), a biosimilar to Lucentis. 2022. https://www.formycon.com/en/press-release/european-commission-approves-f....

MeSH terms